DexCom Inc. has announced the launch of the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System in the United States, expanding its product lineup for adults with diabetes. Beginning December 1, 2025, the new G7 15 Day system will be available to individuals over 18 through durable medical equipment providers, with a broader retail rollout planned in the following weeks. The system offers real-time glucose readings for up to 15.5 days and will be covered for Medicare beneficiaries. Additionally, Dexcom is working to integrate the G7 15 Day with insulin delivery systems such as the iLet Bionic Pancreas and Omnipod 5, with further integrations in development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120288721) on November 20, 2025, and is solely responsible for the information contained therein.